SEHK:2696Biotechs
Assessing Shanghai Henlius Biotech (SEHK:2696) Valuation After China’s Broad HANBEIYOU Approval
Shanghai Henlius Biotech (SEHK:2696) has drawn fresh attention after China’s National Medical Products Administration approved its pertuzumab biosimilar HANBEIYOU for all local reference indications, completing a China, US and EU approval set.
See our latest analysis for Shanghai Henlius Biotech.
Despite the HANBEIYOU catalyst and a string of recent trial starts in oncology and immunology, Shanghai Henlius Biotech’s share price has been under pressure in the near term, with the 7 day and 30...